Improvement in immune dysfunction after FOLFOX chemotherapy for Stage III colon cancer is associated with improved minimal residual disease prognostic subtype and outcome.
Nigel P MurrayRicardo VillalonDan HartmannPatricia Maria RodriguezSocrates AedoPublished in: Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland (2021)
Following chemotherapy, improvements in immune function were associated with improved MRD subtype and a better relapse-free survival.